Catheter Precision to acquire assets of Cardionomic related to CPNS system

Catheter Precision (VTAK) announced that it has signed a definitive agreement to acquire, through its newly formed, 82% owned subsidiary, Cardionomix, Inc. assets of Cardionomic, Inc. relating to its Cardiac Pulmonary Nerve Stimulation, CPNS, System. David Jenkins, CEO of VTAK, commented, “When we were approached by Cleveland Clinic Foundation to take over this project, we could not have been more excited. The original concept and development were a joint effort among Cleveland Clinic, Abbott Labs and NEA, each of which has been impressed by the therapy’s results and were seeking new commercial leadership to take it through FDA approval and to potential commercialization. With demonstrated results, 49 patents issued and a further 46 patent applications, an alignment with the FDA for the pivotal trial, a known reimbursement pathway, and a very large potential market for the technology, we are very pleased to have landed the opportunity and look forward to its future.”